Keeping the host cell line consistent throughout drugdiscovery and drugdevelopment is one of the keystosuccess in protein expression as it decreases the risks during the transition from transient to stable expression.
Consistency and continuity is what Magellan Biologics & Consulting and its sister Company ExcellGene SA offer through their close collaboration.
The CHO4Tx® transient expression system from Magellan is dedicated to discovery, pre-clinical research, a stage where a large variety of candidate proteins has to be screened and only small amounts (mg to g) are needed.
CHO4Tx® cells are derived from and belong to the same line as CHOExpress®, the proprietary cell line from ExcellGene SA, used in stable expression both during clinical development and in the approved drugs’ manufacturing process.
Are you involved in R&D on antibodies ?
Are you planning to screen different protein variants?
We at Magellan Biologics & Consulting proudly support the scientificcommunity in their R&D projects through our CHO4Tx® product portfolio that allows in-house, fast, easy and efficient transient proteinexpression in CHO cells and through personalized advices and consultancies.
A novel drug produced in CHO cells has recently been approved by the FDA
Tislelizumab-jsgr is a PD-1 blocking antibody indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic
29 March 2024
